PEN (Penumbra) Common Stock : $0 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Penumbra Common Stock?

Penumbra's quarterly common stock declined from Jun. 2024 ($0 Mil) to Sep. 2024 ($0 Mil) but then stayed the same from Sep. 2024 ($0 Mil) to Dec. 2024 ($0 Mil).

Penumbra's annual common stock increased from Dec. 2022 ($0 Mil) to Dec. 2023 ($0 Mil) but then declined from Dec. 2023 ($0 Mil) to Dec. 2024 ($0 Mil).

Penumbra Common Stock Historical Data

The historical data trend for Penumbra's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Penumbra Common Stock Chart

Penumbra Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

0.04

Penumbra Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															0.04	0.04	0.04	0.04	0.04

Penumbra Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Penumbra Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Penumbra Inc (NYSE:PEN) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

0P8:Germany

Address

One Penumbra Place, Alameda, CA, USA, 94502

Website

https://www.penumbrainc.com

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.

Executives

Adam Elsesser	director, officer: Chairman, CEO and President	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lambert Shiu	officer: Chief Accounting Officer	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Bridget O'rourke	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Johanna Roberts	officer: EVP, Gen. Counsel & Secretary	PENUMBRA, INC., ONE PENUMBRA PLACE, ALAMEDA CA 94502
Maggie Yuen	officer: Chief Financial Officer	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Arani Bose	director, officer: Chief Innovator	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Harpreet Grewal	director	C/O VISTAPRINT USA, INCORPORATED, 100 HAYDEN AVE., LEXINGTON MA 02050
Don W. Kassing	director	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Surbhi Sarna	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Thomas Wilder	director	2 MUSICK, IRVINE CA 92618
Lynn Rothman	officer: EVP and Chief Business Officer	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
James Robert Pray	officer: President, International	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sridhar Kosaraju	officer: CFO and Head of Strategy	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Janet Leeds	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Robert D. Evans	officer: EVP, Gen. Counsel & Secretary	ONE PENUMBRA PLACE, 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502